PMID- 27789676 OWN - NLM STAT- MEDLINE DCOM- 20170707 LR - 20181113 IS - 1592-8721 (Electronic) IS - 0390-6078 (Print) IS - 0390-6078 (Linking) VI - 102 IP - 3 DP - 2017 Mar TI - Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. PG - 593-599 LID - 10.3324/haematol.2016.145078 [doi] AB - The Revised International Staging System (R-ISS) was recently introduced in order to improve risk stratification over that provided by the widely used standard International Staging System. In addition to the parameters of the standard system, the R-ISS incorporates the presence of chromosomal abnormalities detected by interphase fluorescence in situ hybridization [t(4;14), t(14;16) and del17p] and elevated serum lactate dehydrogenase. The R-ISS was formulated on the basis of a large dataset of selected patients who had participated in clinical trials and has not been validated in an independent cohort of unselected patients. Thus, we evaluated the R-ISS in 475 consecutive, unselected patients, treated in a single center. Our patients were older and more often had severe renal dysfunction than those in the original publication on the R-ISS. As regards distribution by group, 18% had R-ISS-1, 64.5% R-ISS-2 and 18% R-ISS-3. According to R-ISS group, the 5-year survival rate was 77%, 53% and 19% for R-ISS-1, -2 and -3, respectively (P<0.001). The R-ISS could identify three groups with distinct outcomes among patients treated with or without autologous stem cell transplantation, among those treated with either bortezomib-based or immunomodulatory drug-based primary therapy and in patients 75 years. However, in patients with severe renal dysfunction the distinction between groups was less clear. In conclusion, our data in consecutive, unselected patients, with differences in the characteristics and treatment approaches compared to the original International Myeloma Working Group cohort, verified that R-ISS is a robust tool for risk stratification of newly diagnosed patients with symptomatic myeloma. CI - Copyright(c) Ferrata Storti Foundation. FAU - Kastritis, Efstathios AU - Kastritis E AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Terpos, Evangelos AU - Terpos E AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Roussou, Maria AU - Roussou M AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Gavriatopoulou, Maria AU - Gavriatopoulou M AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Migkou, Magdalini AU - Migkou M AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Eleutherakis-Papaiakovou, Evangelos AU - Eleutherakis-Papaiakovou E AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Fotiou, Despoina AU - Fotiou D AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Ziogas, Dimitrios AU - Ziogas D AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Panagiotidis, Ioannis AU - Panagiotidis I AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Kafantari, Eftychia AU - Kafantari E AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Giannouli, Stavroula AU - Giannouli S AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Zomas, Athanasios AU - Zomas A AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Konstantopoulos, Konstantinos AU - Konstantopoulos K AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece. FAU - Dimopoulos, Meletios A AU - Dimopoulos MA AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece mdimop@med.uoa.gr. LA - eng PT - Journal Article DEP - 20161027 PL - Italy TA - Haematologica JT - Haematologica JID - 0417435 RN - 0 (Biomarkers) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers MH - Chromosome Aberrations MH - Cohort Studies MH - Combined Modality Therapy MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence MH - Male MH - Middle Aged MH - Multiple Myeloma/*diagnosis/mortality/therapy MH - Neoplasm Staging MH - Proportional Hazards Models MH - Treatment Outcome PMC - PMC5394955 EDAT- 2016/10/30 06:00 MHDA- 2017/07/08 06:00 PMCR- 2017/03/01 CRDT- 2016/10/30 06:00 PHST- 2016/02/29 00:00 [received] PHST- 2016/10/21 00:00 [accepted] PHST- 2016/10/30 06:00 [pubmed] PHST- 2017/07/08 06:00 [medline] PHST- 2016/10/30 06:00 [entrez] PHST- 2017/03/01 00:00 [pmc-release] AID - haematol.2016.145078 [pii] AID - 1020593 [pii] AID - 10.3324/haematol.2016.145078 [doi] PST - ppublish SO - Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27.